Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs Chemotherapy in Second-line Esophageal Squamous Cell Carcinoma
NCT03787251Phase 2Withdrawn
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Progression-Free Survival at 1 year. Planned start Jan 2019; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03787251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787251.